VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To evaluate the clinical effectiveness and cost-effectiveness of VivaScope® 1500 (Caliber Imaging and Diagnostics, Rochester, NY, USA; Lucid Inc., Rochester, NY, USA; or Lucid Inc., MAVIG GmbH, Munich, Germany) and VivaScope® 3000 (Caliber Imaging and Diagnostics, Rochester, NY, USA) in the diagnosis of equivocal skin lesions, and VivaScope 3000 in lesion margin delineation prior to surgical excision of lesions. Skin cancer is one of the most common cancers in the UK. The main risk factor is exposure to ultraviolet radiation from sunlight or the use of sunbeds. Patients with suspicious skin lesions are first examined with a dermoscope. After examination, those with non-cancerous lesions are discharged, but lesions that are still considered clinically suspicious are surgically removed. VivaScope® is a non-invasive technology designed to be used in conjunction with dermoscopy to provide a more accurate diagnosis, leading to fewer biopsies of benign lesions or to provide more accurate presurgical margins reducing the risk of cancer recurrence.

Authors' conclusions
The use of VivaScope appears to be a cost-effective strategy in the diagnostic assessment of equivocal melanomas and BCCs, and in margin delineation of LM prior to surgical treatment.

Project page URL
http://www.nets.nihr.ac.uk/projects/hta/146902

Final publication URL
http://www.journalslibrary.nihr.ac.uk/hta/hta20580/#/abstract

Additional data URL
http://www.nice.org.uk/guidance/indevelopment/gid-dt23

Indexing Status
Subject indexing assigned by CRD

MeSH
Skin Neoplasms; Sensitivity and Specificity; Melanoma; Image Interpretation, Computer-Assisted; Neoplasm Staging; Image Processing, Computer-Assisted

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

**Address for correspondence**
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

**AccessionNumber**
32015000759

**Date abstract record published**
15/06/2015